A Phase 2/3 interventional study of Tideglusib in Congenital Myotonic Dystrophy, sponsored by AMO Pharma Limited. Recruiting at 14 sites in 4 countries. Open to participants aged 6 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-05-28.
Sponsored by AMO Pharma Limited · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.
Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 6th largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2021, is one of 2 in phase 2/3, reaches primary completion later than 1 of the 26 other live ones, and was the 17th registered.
127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.
Browse Myotonic Dystrophy studies →23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 14+ · Healthy volunteers
Virginia Commonwealth University · Sites in United States
Ages 18–70
Dyne Therapeutics · Sites in United States
Ages 4–18 · Men only
Dyne Therapeutics · Sites in United States, Australia, Belgium and 9 more countries
Ages 16+
Sanofi · Sites in United States, Argentina, Australia and 3 more countries
Ages 10–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.
This study: 6 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 6
First in 2000; this study’s year is marked. 4 started in 2021.
This study's planned enrollment of 76 is above the median of 40 across 68 interventional studies indexed under Myotonic Dystrophy.
Median enrollment 46 across the 22 interventional studies, 125 across the 21 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 43 have an industry lead sponsor. The 10 most frequent:
AMO Pharma Limited is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
AMO Pharma Limited has 4 studies filed under Myotonic Dystrophy — fewer than ten, so there is no comparison to draw.
9 of the studies in Myotonic Dystrophy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004129Phase 3AMO Pharma LimitedSafety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy | 2026-12-31 |
| NCT05020002Massachusetts General HospitalExtracellular RNA Biomarkers of Myotonic Dystrophy | 2026-12 |
| NCT05224778Virginia Commonwealth UniversityDMCRN-02-001: Assessing Pediatric Endpoints in DM1 | 2026-12 |
| NCT03981575Virginia Commonwealth UniversityEstab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | 2026-12-01 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
Add all 9 to your calendar (.ics) → With an account.
Among the 43 studies in Myotonic Dystrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label phase 2/3 study for individuals with Congenital Myotonic Dystrophy (Congenital DM1) who participated in the preceding AMO-02-MD-2-003 study or individuals with either Congenital or Childhood Onset DM1 who are treatment naïve.
This is an open-label study of either a weight-adjusted 1000 mg fixed dose or a weight banded fixed dose of tideglusib across a 52-week treatment period with an open-ended optional extended access period. The subjects are children and adolescents with Congenital DM1 who participated in the antecedent AMO-02-MD-2-003 study or individuals with either Congenital or Childhood onset DM1 who are treatment naïve.
Inclusion Criteria:
Subjects who do not enter this study directly from completing the AMO-02-MD-2-003 study (i.e. subjects who did not complete AMO-02-MD-2-003, subjects who completed AMO-02-MD-2-003 but did not directly rollover or subjects who are re-entering AMO-02-MD-2-004), will not be considered eligible for the study without meeting all of the criteria below:
Subjects entering directly from completing the antecedent AMO-02-MD-2-003 study will not be considered eligible for the study without meeting all of the criteria below:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight adjusted or weight banded tideglusib, orally, once daily
Drug: Tideglusib
Tideglusib dosing will be weight-adjusted at 400 mg, 600 mg, or 1000 mg dose levels, or weight banded fixed doses of 400 mg, 600 mg, 800 mg or 1000 mg, with each subject starting at a weight-adjusted 400 mg dose level for 2 weeks, then up titrating to a weight-adjusted 600 mg dose level for the next 2 weeks.
Safety (Adverse Events)
The incidence of AEs, including SAEs, and abnormal findings in objective assessments (e.g. laboratory values, ECGs and vital signs) from Screening to Enrolment (where applicable), from Enrolment to End of Treatment (52 Weeks), and End of Treatment to the End of Follow-up period.
Time frame: 52 Weeks
Safety (Adverse Events) - With Optional Expanded Access
The incidence of AEs, including SAEs, and abnormal findings in objective assessments (e.g. laboratory values, ECGs and vital signs) from End of Treatment to End of Optional Extended Access, and End of Optional Extended Access to the End of Follow-up period.
Time frame: Week 60 and every 8 weeks thereafter up until discontinuation or study closure, assessed up to Week 132
Clinician-Completed Congenital DM1 Rating Scale (CDM1-RS)
The Clinician-completed Congenital DM1 Rating Scale is an 11-item rating scale completed by the clinician to score the symptom severity of domains that are clinically relevant in Congenital DM1.
Time frame: 52 Weeks
Clinician-Completed Congenital DM1 Rating Scale (CDM1-RS) - With Optional Expanded Access
The Clinician-completed Congenital DM1 Rating Scale is an 11-item rating scale completed by the clinician to score the symptom severity of domains that are clinically relevant in Congenital DM1.
Time frame: Week 68 and every 16 weeks thereafter up until discontinuation or study closure, assessed up to Week 132
Clinical Global Impressions Improvement Scale (CGI-I)
The CGI-I requires the clinician to rate how much the subject's illness has changed (improved, worsened or stayed the same) relative to a baseline state.
Time frame: 54 Weeks
Clinical Global Impressions Improvement Scale (CGI-I) - With Optional Expanded Access
The CGI-I requires the clinician to rate how much the subject's illness has changed (improved, worsened or stayed the same) relative to a baseline state.
Time frame: Week 68 and every 16 weeks thereafter up until discontinuation or study closure, assessed up to Week 132
Top 3 Caregiver Concerns Visual Analogue Scale (VAS) score
The Top 3 concerns VAS allows caregivers to identify their main three causes of concern, related to the subject's myotonic dystrophy, rather than these being pre-specified within a scale and then rating how these concerns have changed at specific time-points during the study.
Time frame: 54 weeks
Top 3 Caregiver Concerns Visual Analogue Scale (VAS) score - With Optional Expanded Access
The Top 3 concerns VAS allows caregivers to identify their main three causes of concern, related to the subject's myotonic dystrophy, rather than these being pre-specified within a scale and then rating how these concerns have changed at specific time-points during the study.
Time frame: Week 68 and every 16 weeks thereafter up until discontinuation or study closure, assessed up to Week 132
Caregiver Completed Congenital DM1 Rating Scale (CC-CDM1-RS)
CC-CDM1-RS provides a caregiver assessment of the subject on symptoms that may occur in individuals with CDM1. There are a total of 11 symptoms that the caregiver is asked to rate from 0 to 4 based on overall severity.
Time frame: 52 weeks
Caregiver Completed Congenital DM1 Rating Scale (CC-CDM1-RS) - With Optional Expanded Access
CC-CDM1-RS provides a caregiver assessment of the subject on symptoms that may occur in individuals with CDM1. There are a total of 11 symptoms that the caregiver is asked to rate from 0 to 4 based on overall severity.
Time frame: Week 68 and every 16 weeks thereafter up until discontinuation or study closure, assessed up to Week 132
Clinical Global Impressions Severity Scale (CGI-S)
The CGI-S is a 7-point Likert type scale that requires the clinician to rate the severity of the subject's illness at the time of assessment, relative to the clinician's past experience with subjects who have the same diagnosis.
Time frame: 54 weeks
Clinical Global Impressions Severity Scale (CGI-S) - With Optional Expanded Access
The CGI-S is a 7-point Likert type scale that requires the clinician to rate the severity of the subject's illness at the time of assessment, relative to the clinician's past experience with subjects who have the same diagnosis.
Time frame: Week 68 and every 16 weeks thereafter up until discontinuation or study closure, assessed up to Week 132
Autism Behavior Inventory- Clinician (ABI-C)
ABI-C is a 14 item rating scale requires the clinician to assess the core features of Autism Spectrum Disorder as well as common associated behaviors.
Time frame: 52 Weeks
Socialization, Communication, Daily Living, and Adaptive Behavior Composite standard scores of the Vineland Adaptive Behavior Scale - Survey Interview
The Vineland Adaptive Behavior Scales require the clinician to measure personal and social skills needed for everyday living. It provides a targeted assessment of adaptive behavior via a semi-structured parent or caregiver interview.
Time frame: 52 Weeks
10-meter walk-run test
The 10-meter walk/run test is a performance measure used to assess walking speed in meters per second over a short distance. It can be used as an assessment of functional mobility.
Time frame: 52 Weeks
Plasma Troponin T levels
Troponin T can be used as a biomarker for cardiac dysfunction but can also be elevated in DM1 patients without evident cardiac dysfunction.
Time frame: 52 Weeks
Plasma Troponin T levels - With Optional Expanded Access
Troponin T can be used as a biomarker for cardiac dysfunction but can also be elevated in DM1 patients without evident cardiac dysfunction.
Time frame: Week 68 and every 16 weeks thereafter up until discontinuation or study closure, assessed up to Week 132
Blood Leukocytes CTG Repeats
A genomic blood sample will be taken from all subjects to confirm the average number of repeats at sampling and estimate the number of leukocyte CTG repeats inherited for an individual subject.
Time frame: Baseline and Week 52
Blood Leukocytes CTG Repeats - With Optional Expanded Access
A genomic blood sample will be taken from all subjects to confirm the average number of repeats at sampling and estimate the number of leukocyte CTG repeats inherited for an individual subject. For subjects that have already passed Week 52 at implementation of this endpoint, a single genomic blood sample will taken at the next in-clinic OEA visit.
Time frame: Week 52 or later
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Started Aug 2021 (actual). Primary completion is estimated for Dec 2026, 64 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tideglusib
AMO Pharma Limited